291 related articles for article (PubMed ID: 22973562)
21. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
[TBL] [Abstract][Full Text] [Related]
22. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery.
Miranda MS; Rodrigues MT; Domingues RMA; Torrado E; Reis RL; Pedrosa J; Gomes ME
Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():1090-1103. PubMed ID: 30274040
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.
Willis L; Hayes D; Mansour HM
Lung; 2012 Jun; 190(3):251-62. PubMed ID: 22274758
[TBL] [Abstract][Full Text] [Related]
24. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.
Sung JC; Garcia-Contreras L; Verberkmoes JL; Peloquin CA; Elbert KJ; Hickey AJ; Edwards DA
Antimicrob Agents Chemother; 2009 Apr; 53(4):1338-43. PubMed ID: 19139288
[TBL] [Abstract][Full Text] [Related]
25. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.
Stewart IE; Lukka PB; Liu J; Meibohm B; Gonzalez-Juarrero M; Braunstein MS; Lee RE; Hickey AJ
Pharm Res; 2019 Jul; 36(9):136. PubMed ID: 31321552
[TBL] [Abstract][Full Text] [Related]
26. Current therapies and technological advances in aqueous aerosol drug delivery.
Watts AB; McConville JT; Williams RO
Drug Dev Ind Pharm; 2008 Sep; 34(9):913-22. PubMed ID: 18663654
[TBL] [Abstract][Full Text] [Related]
27. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
[TBL] [Abstract][Full Text] [Related]
28. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition.
Liao Q; Yip L; Chow MYT; Chow SF; Chan HK; Kwok PCL; Lam JKW
Int J Pharm; 2019 Apr; 560():144-154. PubMed ID: 30731259
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
[TBL] [Abstract][Full Text] [Related]
30. Baicalin/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: Fabrication, characterization, pharmacokinetics, and pharmacodynamics.
Qi D; Jia B; Peng H; He J; Pi J; Guo P; Zhang Y; Deng X; Li J; Liu Z
Eur J Pharm Biopharm; 2023 Jul; 188():243-253. PubMed ID: 37224929
[TBL] [Abstract][Full Text] [Related]
31. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
32. Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.
Braunstein M; Hickey AJ; Ekins S
Pharm Res; 2019 Oct; 36(12):166. PubMed ID: 31650321
[TBL] [Abstract][Full Text] [Related]
33. Particulate pulmonary delivery systems containing anti-tuberculosis agents.
Gupta A; Pandya SM; Mohammad I; Agrawal AK; Mohan M; Misra A
Crit Rev Ther Drug Carrier Syst; 2013; 30(4):277-91. PubMed ID: 23662603
[TBL] [Abstract][Full Text] [Related]
34. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Doyle C; Das SC
Int J Pharm; 2017 Aug; 528(1-2):107-117. PubMed ID: 28583333
[TBL] [Abstract][Full Text] [Related]
35. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin.
Fiegel J; Garcia-Contreras L; Thomas M; VerBerkmoes J; Elbert K; Hickey A; Edwards D
Pharm Res; 2008 Apr; 25(4):805-11. PubMed ID: 17657592
[TBL] [Abstract][Full Text] [Related]
36. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
37. Formulation techniques for high dose dry powders.
Brunaugh AD; Smyth HDC
Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary and Regional Deposition of Nebulized and Dry Powder Aerosols in Ferrets.
Kuehl PJ; Chand R; McDonald JD; Hava DL; DeHaan WH
AAPS PharmSciTech; 2019 Jul; 20(6):242. PubMed ID: 31264190
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs.
Kukut Hatipoglu M; Hickey AJ; Garcia-Contreras L
Int J Pharm; 2018 Oct; 549(1-2):306-316. PubMed ID: 30077761
[TBL] [Abstract][Full Text] [Related]
40. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
